Georgios Tsakonas
0000-0003-4397-7391
Karolinska Institute
25 papers found
Refreshing results…
Validation of the ALK-Brain Prognostic Index for patients with ALK-rearranged lung cancer and brain metastases
Safety and efficacy of immune checkpoint blockade in patients with advanced nonsmall cell lung cancer and brain metastasis
Matched Analyses of Brain Metastases versus Primary Non-Small Cell Lung Cancer Reveal a Unique microRNA Signature
Ras-Related Protein Rab-32 and Thrombospondin 1 Confer Resistance to the EGFR Tyrosine Kinase Inhibitor Osimertinib by Activating Focal Adhesion Kinase in Non-Small Cell Lung Cancer
High Density of NRF2 Expression in Malignant Cells Is Associated with Increased Risk of CNS Metastasis in Early-Stage NSCLC
Correlation of Clinical Parameters with Intracranial Outcome in Non-Small Cell Lung Cancer Patients with Brain Metastases Treated with Pd-1/Pd-L1 Inhibitors as Monotherapy
High-dose versus standard-dose twice-daily thoracic radiotherapy for patients with limited stage small-cell lung cancer: an open-label, randomised, phase 2 trial
Extending hypofractionated stereotactic body radiotherapy to tumours larger than 70cc – effects and side effects
Effect of corticosteroids on the outcome of patients with advanced non–small cell lung cancer treated with immune-checkpoint inhibitors
Outcome of Patients with NSCLC and Brain Metastases Treated with Immune Checkpoint Inhibitors in a ‘Real-Life’ Setting
Randomized Phase II Study with Cetuximab in Combination with 5-FU and Cisplatin or Carboplatin Vs. Cetuximab in Combination with Paclitaxel and Carboplatin for Treatment of Patients with Relapsed or Metastatic Squamous Cell Carcinoma of the Head and Neck (CETMET Trial)
Treatment of rheumatic immune-related adverse events due to cancer immunotherapy with immune checkpoint inhibitors—is it time for a paradigm shift?
ALK-Brain Prognostic Index—Preliminary Study of a Prognostic Tool for Patients with ALK-Rearranged, Non-small Cell Lung Cancer and Brain Metastases
An immune gene expression signature distinguishes central nervous system metastases from primary tumours in non–small-cell lung cancer
Primary CNS metastatic BRAF mutated lung adenocarcinoma with complete intracranial response to BRAF/MEK inhibition
Immune checkpoint blockade for non–small cell lung cancer: What is the role in the special populations?
c-MET as a biomarker in patients with surgically resected non-small cell lung cancer
Corrigendum to “Validation of the 8th TNM classification for small-cell lung cancer in a retrospective material from Sweden” [Lung Cancer 120 (June) (2018) 75–81]
Validation of the 8th TNM classification for small-cell lung cancer in a retrospective material from Sweden
Oncogene-addicted non-small cell lung cancer and immunotherapy
Missing publications? Search for publications with a matching author name.